Logo image of CRVS

CORVUS PHARMACEUTICALS INC (CRVS) Stock Price, Quote, News and Overview

NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD

3.565  -0.06 (-1.79%)

CRVS Quote, Performance and Key Statistics

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (5/22/2025, 3:08:02 PM)

3.565

-0.06 (-1.79%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10
52 Week Low1.75
Market Cap243.03M
Shares68.17M
Float54.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04
IPO03-23 2016-03-23


CRVS short term performance overview.The bars show the price performance of CRVS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

CRVS long term performance overview.The bars show the price performance of CRVS in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of CRVS is 3.565 USD. In the past month the price increased by 3.13%. In the past year, price increased by 76.21%.

CORVUS PHARMACEUTICALS INC / CRVS Daily stock chart

CRVS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.81 323.48B
AMGN AMGEN INC 13.07 145.92B
GILD GILEAD SCIENCES INC 13.81 133.07B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.14B
REGN REGENERON PHARMACEUTICALS 13.43 64.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.62B
ARGX ARGENX SE - ADR 99.06 35.50B
ONC BEIGENE LTD-ADR 5.93 25.73B
BNTX BIONTECH SE-ADR N/A 23.81B
NTRA NATERA INC N/A 20.92B
SMMT SUMMIT THERAPEUTICS INC N/A 19.12B
BIIB BIOGEN INC 8.01 18.56B

About CRVS

Company Profile

CRVS logo image Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 31 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Company Info

CORVUS PHARMACEUTICALS INC

863 Mitten Rd Ste 102

Burlingame CALIFORNIA 94010 US

CEO: Richard A. Miller

Employees: 31

CRVS Company Website

CRVS Investor Relations

Phone: 16509004520

CORVUS PHARMACEUTICALS INC / CRVS FAQ

What is the stock price of CORVUS PHARMACEUTICALS INC today?

The current stock price of CRVS is 3.565 USD. The price decreased by -1.79% in the last trading session.


What is the ticker symbol for CORVUS PHARMACEUTICALS INC stock?

The exchange symbol of CORVUS PHARMACEUTICALS INC is CRVS and it is listed on the Nasdaq exchange.


On which exchange is CRVS stock listed?

CRVS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CORVUS PHARMACEUTICALS INC stock?

12 analysts have analysed CRVS and the average price target is 15.3 USD. This implies a price increase of 329.17% is expected in the next year compared to the current price of 3.565. Check the CORVUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CORVUS PHARMACEUTICALS INC worth?

CORVUS PHARMACEUTICALS INC (CRVS) has a market capitalization of 243.03M USD. This makes CRVS a Micro Cap stock.


How many employees does CORVUS PHARMACEUTICALS INC have?

CORVUS PHARMACEUTICALS INC (CRVS) currently has 31 employees.


What are the support and resistance levels for CORVUS PHARMACEUTICALS INC (CRVS) stock?

CORVUS PHARMACEUTICALS INC (CRVS) has a support level at 3.39 and a resistance level at 3.64. Check the full technical report for a detailed analysis of CRVS support and resistance levels.


Should I buy CORVUS PHARMACEUTICALS INC (CRVS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CORVUS PHARMACEUTICALS INC (CRVS) stock pay dividends?

CRVS does not pay a dividend.


When does CORVUS PHARMACEUTICALS INC (CRVS) report earnings?

CORVUS PHARMACEUTICALS INC (CRVS) will report earnings on 2025-08-04.


What is the Price/Earnings (PE) ratio of CORVUS PHARMACEUTICALS INC (CRVS)?

CORVUS PHARMACEUTICALS INC (CRVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).


What is the Short Interest ratio of CORVUS PHARMACEUTICALS INC (CRVS) stock?

The outstanding short interest for CORVUS PHARMACEUTICALS INC (CRVS) is 10.69% of its float. Check the ownership tab for more information on the CRVS short interest.


CRVS Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CRVS. When comparing the yearly performance of all stocks, CRVS is one of the better performing stocks in the market, outperforming 93.03% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CRVS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CRVS. CRVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRVS Financial Highlights

Over the last trailing twelve months CRVS reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -17.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -90.4%
ROE -191.27%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%275%
Sales Q2Q%N/A
EPS 1Y (TTM)-17.31%
Revenue 1Y (TTM)N/A

CRVS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to CRVS. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners43.45%
Ins Owners3.91%
Short Float %10.69%
Short Ratio5.38
Analysts
Analysts86.67
Price Target15.3 (329.17%)
EPS Next Y50.63%
Revenue Next YearN/A